UBS Group Initiates Coverage on Perspective Therapeutics (NYSE:CATX)

Research analysts at UBS Group assumed coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research report issued on Thursday, Briefing.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. UBS Group’s price target would indicate a potential upside of 71.09% from the company’s current price.

CATX has been the topic of a number of other research reports. Wedbush assumed coverage on shares of Perspective Therapeutics in a research note on Tuesday, October 1st. They set an “outperform” rating and a $25.00 target price on the stock. Oppenheimer restated an “outperform” rating and set a $22.00 price objective on shares of Perspective Therapeutics in a research report on Friday, October 11th. Truist Financial began coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price for the company. Royal Bank of Canada reduced their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a report on Friday, August 16th. Finally, Bank of America assumed coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $21.25.

Perspective Therapeutics Trading Down 5.6 %

NYSE:CATX opened at $11.69 on Thursday. Perspective Therapeutics has a twelve month low of $2.20 and a twelve month high of $19.05. The company has a 50-day simple moving average of $13.84.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. The company had revenue of $0.53 million during the quarter. Equities analysts predict that Perspective Therapeutics will post -0.87 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

Several institutional investors have recently added to or reduced their stakes in CATX. Vanguard Group Inc. lifted its holdings in Perspective Therapeutics by 34.6% in the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after buying an additional 4,566,356 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Perspective Therapeutics in the 1st quarter valued at about $15,511,000. Affinity Asset Advisors LLC bought a new position in Perspective Therapeutics during the first quarter worth $6,069,000. Nicholson Wealth Management Group LLC acquired a new stake in Perspective Therapeutics in the third quarter worth $21,390,000. Finally, Ally Bridge Group NY LLC bought a new stake in Perspective Therapeutics in the second quarter valued at $3,951,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.